We compared the clinical outcomes of single-and three-fraction stereotactic body radiation therapy schedules for early-stage nonesmall-cell lung cancer (n [ 159). No statistically significant differences in clinical outcomes between these 2 regimens were observed, although the single-fraction group included more patients with worse performance status, suggesting a single-fraction regimen is a reasonable option. Background: To compare the clinical outcomes of patients with early-stage nonesmall-cell lung cancer (NSCLC) who had undergone either single-fraction (SF) or three-fraction (TF) stereotactic body radiation therapy (SBRT) at a single institution during over 8-year period. Patients and Methods: Patients with peripherally located early-stage NSCLC who had undergone SBRT from February 2007 to November 2015 were included in the present study. SBRT was delivered without heterogeneity correction. Data were retrospectively reviewed and collected in an institutional review board-approved database. R software (version 3.3.2) was used for statistical analysis. Results: Of 159 total lung tumors, 65 lesions received 30 Gy (median, 30 Gy) in 1 fraction, and 94 lesions received 48 to 60 Gy (median, 60 Gy) in 3 fractions. Patients with a Karnofsky performance status < 80 were more common in the SF-SBRT cohort (P ¼ .050). After a median follow-up of 22.2 and 26.2 months for the SF-SBRT and TF-SBRT cohorts, respectively (P ¼ .29), no statistically significant difference was found in overall survival (P ¼ .86), progression-free survival (P ¼ .95), local failure (P ¼ .95), nodal failure (P ¼ .91), and distant failure (P ¼ .49) at 24 months. At 1 and 2 years, the overall survival rates were 86.1% and 63.2% for the SF-SBRT cohort and 80.8% and 61.6% for the TF-SBRT cohort, respectively. At 1 and 2 years, the local control rates were 95.1% and 87.8% for the SF-SBRT cohort and 92.7% and 86.2% for the TF-SBRT cohort, respectively. Both regimens were well tolerated. Conclusion: Despite more patients with poor performance status in the SF-SBRT cohort, the SF-and TF-SBRT regimens showed no differences in clinical outcomes. SF-SBRT is now our standard approach.
Introduction
Surgery remains the standard treatment for early-stage nonesmallcell lung cancer (NSCLC) with a 5-year survival rate of 50% to 80%. 1, 2 Medically inoperable patients historically received either conventionally fractionated radiation therapy or stereotactic body radiation therapy (SBRT). In a recent trial, SBRT was shown to be better tolerated with improved disease control. 3 Further studies of SBRT have demonstrated a local control rate of > 90% with overall survival (OS) and progression-free survival (PFS) rates comparable to those with surgery alone. [4] [5] [6] [7] Early-stage NSCLC can be categorized by its location relative to the proximal bronchial tree. 8 Both single-fraction (SF) and threefraction (TF) SBRT have shown to be reasonably well tolerated for peripherally located tumors (> 2 cm away from the proximal bronchial tree) in previous studies, including Radiation Therapy Oncology Group (RTOG) trial 0915. 6, [9] [10] [11] [12] [13] These regimens have been compared in a multi-institutional, phase II, randomized study led by our institution, which has been reported in abstract form and showed equivalent outcomes and toxicities. 12 Pending the final results of that prospective trial and understanding that trial participation itself could affect the outcomes, 14 we retrospectively investigated how these regimens performed in our clinical practice.
Patients and Methods

Patients
We retrospectively reviewed the data from 155 patients who had received definitive SF-or TF-SBRT for peripheral NSCLC from February 2007 to November 2015. Data were collected and maintained in an institutional review board-approved database at Roswell Park Cancer Institute (RPCI). Clinical trial patients who participated in the RTOG 0915 trial were excluded from the present analysis as the doses used in that study were different from the doses used in the our analysis. Patients treated at RPCI in the multiinstitutional randomized study I-124407 were randomized to the doses used in the present analysis and thus were included. All patients were screened for eligibility at the time of consultation and offered trial enrollment if eligible; many patients, however, simply refused to participate and were treated off-protocol at the discretion of the treating physician.
When treated off-protocol, a combination of factors (radiation oncologist preference, performance status, setup, and transportation issues) were considered in the decision regarding the number of fractions. In the initial period, SF therapy was preferred for those with poor performance status, poor social support, poor access to transportation, and poor reproducibility of their treatment position in part owing to other medical comorbidities. Over time as experience with SF increased, this became a more preferred approach of the treating radiation oncologists.
Staging and Operative Evaluation
Before SBRT, all patients underwent an initial consultation for history taking and physical examination and a discussion of the treatment options and their risks and benefits. Axial computed tomography (CT) and fluorodeoxyglucose-positron emission tomography (PET) scans were included in most cases at the consultation. Endoscopic bronchoscopic ultrasonography was routinely performed as clinically indicated. The cases of all patients were presented at a multidisciplinary conference. Medical inoperability was determined using thoracic surgeons-based factors such as poor pulmonary function, including a forced expiratory volume in 1 second < 40% of predicted, cardiovascular comorbidities, including unstable angina, and poor performance status.
Treatment Planning
The delivery method of SBRT at RPCI has been previously reported. 15 Normal tissue constraints were those used in RTOG 0915
for SF-SBRT and RTOG 0236 for TF-SBRT. 6, 11 Threedimensional conformal radiation therapy with 11 non-coplanar fields was used in most cases. Intensity-modulated radiation therapy was used for 2 patients in the SF-SBRT and 3 patients in the TF-SBRT cohorts. Heterogeneity corrections were used only for patients treated with intensity-modulated radiation therapy. The gross tumor volume (GTV) was outlined on each CT slice, and tumors were distinguished from adjacent structures using lung and soft tissue windows. The clinical target volume was defined as equal to the GTV. The internal target volume was created using 4-dimensional CT. The planning target volume (PTV) was generated from the internal target volume with a 0.5-cm margin added uniformly. The prescription dose was delivered to the edge of the PTV. The prescription isodose surface was between 60% and 90% of the maximum dose, and 99% of the PTV received 90% of the prescription dose.
Follow-up
Follow-up appointments were scheduled at 1.5, 3, and 6 months after SBRT. Subsequent follow-up visits occurred every 6 months for 2 years and annually thereafter. PET/CT at the 1-year follow-up visit and surveillance CT of the chest during the other visits were performed to assess the tumor response to SBRT.
Outcomes Assessment
Local failure was considered as tumor recurrence in the PTV or in the treated lobe of the lung. If a local lesion was PET-avid and no biopsy was performed, it was classified as local failure. If no PET scan was performed and our radiologists reading the CT scan believed that a lesion might be even slightly concerning for malignancy, we also classified it as local failure. Nodal failure was considered as tumor recurrence in the regional lymph nodes along the natural lymphatic drainage from the location of the primary tumor. Distant failure was considered as tumor recurrence in uninvolved lobes or other organs.
We evaluated toxicity retrospectively from the clinical database using the Common Terminology Criteria for Adverse Events, version 4.0. Toxicities were categorized as either acute or late according to whether they occurred within 30 days of SBRT completion or afterward. Patients with multiple toxicities were counted only once as having the toxicity with the highest grade. Only toxicities directly attributable to radiation treatment were included for analysis. Other adverse events considered to be caused by pre-existing respiratory comorbidities, such as chronic obstructive pulmonary disease exacerbation and pneumonia, were excluded.
Statistical Analysis
OS and PFS were assessed using the Kaplan-Meier method and log-rank tests. Local, nodal, and distant failures were evaluated using the competing risks method and Gray's tests. Potential prognostic factors were analyzed using the Cox proportional hazards method. Categorical and continuous variables between the 2 treatment cohorts were compared using Fisher's exact test and the MannWhitney U test, respectively.
All P values were 2-sided. P values 0.05 were considered statistically significant. R software, version 3.3.2 (R Foundation for Statistical Computing, Vienna, Austria), was used for all analyses.
Results
Baseline Characteristics
A total of 155 patients with 159 early-stage NSCLC tumors were evaluated. The patient characteristics are described in 
Outcomes
After a median follow-up period of 22.2 months (IQR, 14.1-31.7 months) for SF-SBRT and 26.2 months (IQR, 14.5-39.7 months) for TF-SBRT (P ¼ .29), no statistically significant difference was found between the 2 cohorts in OS (P ¼ .86), PFS (P ¼ .95), local failure (P ¼ .95), nodal failure (P ¼ .91), or distant failure (P ¼ .49) at 24 months (Figures 1-4) . The 1-and 2-year OS rates were 86.1% and 63.2% for the SF-SBRT cohort and 80.8% and 61.6% for the TF-SBRT cohort, respectively. The 1-and 2-year local control rates were 95.1% and 87.8% for the SF-SBRT cohort and 92.7% and 86.2% for the TF-SBRT cohort, respectively. The 1-and 2-year distant control rates were 91.6% and 84.3% for the SF-SBRT cohort and 82.6% and 72.0% for the TF-SBRT cohort, respectively.
Twenty-eight pneumonia and chronic obstructive pulmonary disease exacerbation cases were excluded from analysis because they occurred 10 months after SBRT and were considered to be consistent with pre-existing respiratory comorbidities. No grade 3 pulmonary toxicity was reported within 6 months after SBRT. No grade 3 toxicity in the SF-SBRT group was reported, and only 1 case of grade 3 pulmonary embolism occurred in the TF-SBRT cohort. This case of pulmonary embolism was retrospectively reviewed again. It was not excluded from the analysis, because this patient had not had any pulmonary embolism before SBRT and a recent registry study showed that radiation therapy was associated with a greater risk of pulmonary embolism. 16 
Sung Jun Ma et al
Clinical Lung Cancer March 2018 -e237
Discussion
The present retrospective review of 155 patients with peripheral early-stage NSCLC compared the clinical outcomes of SF-and TF-SBRT cohorts. To the best of our knowledge, this is the largest comparison of these regimens reported. Although the SF-SBRT cohort included more patients with a worse performance status, our SF-and TF-SBRT cohorts showed no significant differences in OS, PFS, local control, nodal control, distant control, or toxicity. This finding is consistent with the preliminary reports from our phase II randomized multi-institutional trial that showed equivalent OS (71% for SF and 61% for TF regimens; P ¼ .44) and PFS (63% for SF and 51% for TF regimens; P ¼ .99) at 2 years. 12 The OS, PFS, and local control rates in the current SF-SBRT cohort were comparable to those from other studies. 9, [11] [12] [13] 17, 18 The outcomes of the TF-SBRT cohort were similarly comparable to those from previous studies. 6, 8, 12, [19] [20] [21] The distant failure rate at 1 year for our SF-SBRT cohort was 8.4%, lower than that reported by other studies of SF-SBRT, likely because we had smaller tumor lesions in our cohort. 17, 18 A larger tumor lesion has been shown to be associated with the development of distant failure. [22] [23] [24] The TF-SBRT cohort had a distant failure rate at 1 year of 17.4%, comparable to that from previous studies. [24] [25] [26] [27] [28] Both SF-and TF-SBRT regimens were well tolerated in our study, similar to those reported previously. 6, 8, 9, 11, 13, 20 In our study, decreasing tumor size was a favorable prognostic factor for OS. This finding is consistent with those from previous studies. 19, [29] [30] [31] [32] However, increasing tumor size was not associated with greater local, nodal, or distant failure rates in our study, in contrast to those reported previously. [22] [23] [24] This observation might have resulted in part from the small sample size of those with stage T2 disease in our analysis, at only 20% to 24% of patients in each cohort. In our cohorts, medical inoperability was not associated with worse clinical outcomes. The Japan Clinical Oncology Group 0403 study similarly showed that OS and toxicities were comparable between medically operable and inoperable patients. 33 In addition to the intrinsic limitations of retrospective reviews, the sample size of our patient cohorts was small and the follow-up duration was short. Other variables were not collected in our database, such as the cause of death, second-line treatments after initial disease progression if offered, Charlson comorbidity index, GTV, frequency of other staging modalities such as endoscopic bronchoscopic ultrasonography, grade 2 toxicity, and routine pulmonary function test results.
Several prospective, multicenter clinical trials are currently awaiting publication of mature data to compare different SBRT regimens for early-stage NSCLC. 11, 12 In the interval, from the results of the present analysis and the early data from I-124407, we have adopted SF-SBRT as our institutional standard. 
Conclusion
The SF-and TF-SBRT cohorts showed no statistically significant differences in clinical outcomes. The similarity in clinical outcomes between these 2 schedules is notable, because patients with a worse performance status tended to receive SF-SBRT. SF-SBRT is now our institutional standard regimen.
Clinical Practice Points
Previous evidence has shown that both SF-and TF-SBRT are well tolerated for early-stage medically inoperable peripheral NSCLC. Although our SF-SBRT cohort included more patients with a worse performance status, no statistically significant differences were found in the clinical outcomes between the 2 regimens. The SF-SBRT regimen is a reasonable treatment option for earlystage peripheral NSCLC.
